Mar 31, 2022

Clover Health Q1 2022 Earnings Report

Clover Health reported strong revenue growth and margin improvements.

Key Takeaways

Clover Health's Q1 2022 results showed significant year-over-year revenue growth, driven by increases in both Insurance and Non-Insurance segments. The company is focused on balancing growth with MCR reduction and operational efficiencies to drive towards profitability. Total revenue was $874.4 million, compared to $200.3 million in Q1 2021. Lives under Clover Management grew to approximately 257,000 from approximately 66,000 year-over-year.

Total revenue reached $874.4 million, a substantial increase from $200.3 million in the first quarter of 2021.

Lives under Clover Management grew to approximately 257,000, up from approximately 66,000 year-over-year.

Insurance (Medicare Advantage) Medical Care Ratio (MCR) was 96.4%, showing significant improvement.

Non-Insurance (Direct Contracting) MCR was 99.8%, also indicating quarter-over-quarter improvement.

Total Revenue
$874M
Previous year: $200M
+336.5%
EPS
-$0.16
Previous year: -$0.12
+33.3%
Gross Profit
$12.7M
Previous year: -$14.1M
-189.7%
Cash and Equivalents
$274M
Previous year: $720M
-62.0%
Free Cash Flow
-$57.2M
Previous year: -$93M
-38.5%
Total Assets
$2.68B
Previous year: $867M
+209.1%

Clover Health

Clover Health

Forward Guidance

Clover Health reaffirms its full-year 2022 guidance, expecting total revenues between $3.0 billion and $3.4 billion and an Insurance MCR between 95% and 99%.

Positive Outlook

  • Total revenues are expected to be in the range of $3.0 billion to $3.4 billion.
  • Insurance revenue is projected to be $1.0 billion to $1.1 billion.
  • Non-Insurance revenue is projected to be $2.0 billion to $2.3 billion.
  • Insurance membership is expected to average 84,000 - 85,000, a growth rate of 26% - 27% as compared to the 2021 average.
  • Insurance MCR is expected to be in the range of 95% - 99%.

Challenges Ahead

  • Significant developments related to COVID-19 and/or historical utilization trends could impact expectations.
  • Stock-based compensation expense cannot be reasonably calculated or predicted at this time without unreasonable efforts.
  • Challenges in expanding member and beneficiary base or into new markets.
  • Exposure to unfavorable changes in local benefit costs, reimbursement rates, competition and economic conditions.
  • The current and future impact of the COVID-19 pandemic and its variants on Clover Health’s business and industry.